Leukemia Inhibitory Factor and Bronchial Asthma

NIU Cong,ZHU Hui-li

DOI: https://doi.org/10.3760/cma.j.issn.1673-436x.2012.019.009

2012-01-01

Abstract:In the development of bronchial asthma (asthma),there is complex interactions between neuro immuno-endocrine systems,which is a multistep process involving varieties of cytokines,inflammation mediators and neurotransmitters.Leukemia inhibitory factor (LIF) functions as a critical molecular interface between neuro-immuno-endocrine systems and it is an important factor in asthma pathogenesis.LIF can activate a variety of inflammatory cells including eosinophils,lymphocytes and mast cells,promoting the release of inflammatory mediators.LIF not only increases substance p expression in airway neurons but also increases the number of neurokinin-1 receptor (NK 1R) in bronchial epithelial cell.LIF maintains the HPA axis activiation by decreasing glucocorticoid receptor expression and raise the possibility that LIF might contribute to the development of central glucocorticoid resistance during inflammation.It has been shown that LIF plays significant pathphysioloical roles in asthma induction,is highly elevated in serum,sputum,bronchioalveolar lavagefluid and epithelia cell of asthma patient.This review describes the brological characters of LIF and the relationship with asthma,so as to explore the pathogenesis of asthma and provide the theoretical basis for clinical treatment.